At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 78 enrolled
Drug / intervention
Oxymorphone ER +3 moredrug
Likely dose
Oxymorphone ER 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory, Single-Dose, Double-Blind, Randomized, Placebo-Controlled Crossover Study to Evaluate The Subjective and Objective Effects of Extended-Release Oxymorphone Compared to Controlled-Release Oxycodone in Healthy Non-Dependent Recreational Opioid Users
In Brief
A Phase 4 clinical trial evaluating Oxymorphone ER, Oxycodone CR, and 2 other interventions for Healthy. Completed, enrolled 78 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsKendle Early Stage - Toronto
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedAug 2009
Primary CompletionSep 2009
TodayJul 2026
First PostedAug 7, 2009
Enrollment StartJun 1, 2009
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.9 years ago
Interventions
Oxymorphone ERdrug
15mg or 30mg
Oxycodone CRdrug
30mg or 60mg
Placebodrug
The placebo was a sugar pill.
Hydromorphonedrug
8 mg